The NH2-terminal amino acid sequence of type 12 M protein was determined by automated Edman degradation of a 38-kilodalton polypeptide fragment purified from a limited pepsin digest of intact type 12 streptococci. The sequence of the first 13 amino acid residues of the polypeptide confirmed that predicted by the nucleotide sequence of the mature type 12 M protein. A chemically synthesized peptide copying the NH2-terminal 25 residues, SM12(1-25)C, evoked opsonic antibodies against type 12 streptococci as well as renal glomerular cross-reactive antibodies. The serum from one of six rabbits reacted in immunofluorescence tests with human glomeruli in a mesangial staining pattern. The cross-reactive antibodies were completely inhibited by the immunizing peptide and absorption with type 12 streptococci. Subpeptides of the 25-residue synthetic peptide were without inhibitory effect, suggesting that the cross-reactive antibodies are directed against a conformational epitope of SM12(1-25)C. Anti-SM12(1-25)C antisera reacted specifically with the intermediate ifiament protein vimentin extracted from mesangial cells. None of the cross-reactions of anti-SM12(1-25)C were inhibited by a synthetic peptide SM1(1-26)C of type 1 M protein, which was previously shown to share a cross-reactive epitope with vimentin. These results indicate that type 12 M protein contains at least one vimentin cross-reactive epitope that is clearly distinct from the tetrapeptide epitope shared with vimentin by type 1 M protein.
The M protein molecules of group A streptococci form a-helical coiled-coil fibrils radiating from the surface of virulent strains of Streptococcus pyogenes (24) . The fibrils confer on the organisms resistance to recognition and ingestion by phagocytes of the nonimmune host (28) . Only antibodies directed towards protective epitopes on the M protein molecule render the organisms susceptible to phagocytosis and killing in the immune host (22) . In addition to its protective epitopes, certain M protein molecules contain epitopes capable of eliciting autoimmune reactions with specific host tissues. Sequences of rheumatogenic serotypes 5, 6 , and 19 M proteins have been shown to evoke antibodies that react with myosin, tropomyosin, and other as yet unidentified myocardial and skeletal muscle proteins (8, 10-12, 14, 20, 27) . Recently, it has become clear that M proteins of nephritogenic types 1 and 12 share antigenic determinants with renal glomeruli (16, 17) . These autoimmune properties of various M proteins have hampered the development of a safe and effective vaccine against streptococcal infections.
Previous studies have shown that synthetic peptides copying NH2-terminal sequences of types 5, 6 , and 24 M proteins contain protective but not autoimmune epitopes (1) (2) (3) (4) (5) 13 filament protein extracted from renal glomerular mesangial cells. In this study, we report that the NH2-terminal region of the M protein of nephritogenic type 12 streptococci specifies vimentin cross-reactive epitopes that are distinct from those specified by the NH2-terminal region of type 1 M protein.
MATERIALS AND METHODS
Proteins. Purified bovine vimentin (57 kilodaltons) and purified chicken desmin (53 kilodaltons) were purchased from ICN Immunobiologicals (Lisle, Ill.). They were judged to be pure by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis as previously described (19) . Pepsinextracted M protein of type 24 streptococci (pep M24) was purified in a previous study (6) .
Extraction and purification of streptococcal M protein. Polypeptide fragments of type 12 M protein were extracted from intact type 12 group A streptococci (strain SF42) by limited pepsin digestion at pH 5.8 and were partially purified by ammonium sulfate precipitation and ion-exchange chromatography over DEAE-cellulose as previously described (6) . To affinity purify pep M12 fragments containing the NH2 terminus of the mature type 12 M protein, the immunoglobulin G fraction of antiserum raised against the synthetic peptide SM12(1-25)C was purified over DEAE-cellulose. The purified immunoglobulin G fraction was coupled to Affi-Gel 10 (Bio-Rad Laboratories, Rockville Centre, N.Y.) by following the instructions given by the manufacturer, and partially purified pep M12 fragments were applied to the immunoglobulin G-Affi-Gel 10 column. The bound material was eluted with 0.2 M glycine-0.5 M NaCl, pH 2.3, neutralized, dialyzed extensively against 0.01 M NH4HCO3, and lyophilized. The homogeneity of the purified pep M12 was judged by SDS-polyacrylamide gel electrophoresis.
SDS-polyacrylamide gel electrophoresis and Western blots. SDS-polyacrylamide gel electrophoresis was performed on 12% polyacrylamide slab gels according to the method of Laemmli (21) , and Western blots were performed as previously described by Towbin et al. (29) .
Analytical methods. Quantitative amino acid analysis was performed on peptide samples hydrolyzed in constant boiling HCl with an automatic amino acid analyzer (Beckman, Model 121 MB). Amino acid sequence analysis was performed with a Beckman microsequenator (Model 890C) according to the principles first described by Edman and Begg (15) and as previously described (4) .
Synthesis and conjugation of M protein peptides. Several overlapping peptide copies of the NH2-terminal region of type 12 M protein (25) were synthesized by the solid-phase method of Merrifield (23) as described (7) . The synthetic peptides were cleaved, deblocked, and purified by gel filtration on a column of Sephadex G10 (Pharmacia Fine Chemicals, Uppsala, Sweden) as previously described (4) . The purity and composition of the peptide were assured by high-pressure liquid chromatography on Ultrasphere ODS2 (Whatman Laboratory Products, Inc., Clifton, N.J.), by quantitative amino acid analyses, and by automated Edman degradation to the penultimate amino acid residue (4) . The peptides were synthesized with a COOH-terminal cysteine to enable coupling to a carrier molecule with a bifunctional cross-linking reagent. The peptides synthesized for this study are designated SM12(1-25)C, SM12(1-12)C, SM12(13-25)C, and SM12(7-18)C. The peptides SM1(1-26)C, SV(63-73)C, and SV(178-188)C were synthesized in previous studies (17, 19) .
The peptide SM12(1-25)C was conjugated through its COOH-terminal cysteine residue to keyhole limpet hemocyanin or pep M24 (6) as described (30) with the modification of Rothbard et al. (26) .
Immunization of rabbits. Sets of three New Zealand White rabbits (2 kg) were injected subcutaneously with 100-nmol doses of synthetic peptide SM12(1-25)C conjugated to keyhole limpet hemocyanin or pep M24 and emulsified in complete Freund adjuvant as described (13) . Booster injections consisting of the same dose in 0.02 M phosphate-0.15 M NaCl, pH 7.4, were given at 4, 8, and 10 weeks. Rabbits were bled before and at 2-week intervals after the initial injection. All sera were heat inactivated at 56°C for 30 min and stored in sterile vials at 4°C. Antiserum 8652 raised against SM1(1-19) (23-26)C in a previous study (18) was also used in this study.
Assays for anti-M protein antibodies. The immune rabbit sera were assayed for antibodies against M protein by enzyme-linked immunosorbent assay (ELISA) (17), opsonophagocytosis, and indirect bactericidal tests (4) . The peptide specificity of the opsonic antibodies directed against type 12 streptococci was tested by opsonization inhibition tests (4) . Samples of opsonic antisera, diluted in 0.02 M phosphate-0.15 M NaCl, pH 7.4, to the highest dilution that promoted phagocytosis of homologous type 12 streptococci, were preincubated for 30 min at 37°C with synthetic peptides at a concentration of 100 ,uM or with 1 mg of vimentin or desmin per ml before addition to the opsonization test mixture. Phagocytosis was expressed as the percentage of polymorphonuclear leukocytes associated with streptococci in 50 counted leukocytes after rotating the test mixtures endover-end at 37°C for 45 min.
Detection of tissue cross-reactive antibodies. Preimmune and immune sera were tested for the presence of tissue cross-reactive antibodies with frozen sections (4 ,um thick) of normal human renal cortex or human myocardium by indirect immunofluorescence assays (9, 10 (6) . The crude digest was purified by ammonium sulfate precipitation, ion-exchange chromatography over DEAE-cellulose (6) , and affinity chromatography over Affi-Gel 10 to which the IgG fraction of antiserum raised against SM12(1-25)C had been coupled. The purified protein migrated as a single polypeptide on an SDS-polyacrylamide gel with an apparent molecular weight of 38,000 (Fig. 1) . The amino acid sequence of the purified protein was determined by automated Edman degradation (4), and the NH2-terminal 13 residues were found to 
The sequence of the NH,-terminal region of type 12 M protein was determined partially by automated Edman degradation and was predicted by nucleotide sequence analysis of the type 12 M protein gene (25) .
" Underlined cysteine residues were added for the purpose of coupling to a carrier.
against M type 12 streptococci ( Although none of the six antisera reacted with sarcolemmal membranes of human myocardium, one of three antisera raised against SM12(1-25)C conjugated to keyhole limpet hemocyanin reacted with renal glomeruli in a mesangial cell pattern as determined by immunofluorescence tests of frozen sections of human renal cortex (Table 3) . Thus, the NH2-terminal 25 residues of type 12 M protein contain type-specific opsonic epitopes as well as kidney crossreactive epitopes.
Localization of protective and glomerular cross-reactive epitopes of SM12(1-25)C. To identify the protective and glomerular cross-reactive epitopes of the NH, terminus of type 12 M protein, we used overlapping peptides in opsonization and immunofluorescence inhibition tests. Opsonization of type 12 streptococci by antiserum 86142 (diluted 1:32) was totally inhibited by preincubation with type 12 streptococci or SM12(1-25)C, the immunogen (Table 4) . The subpeptides SM12(1-12)C, SM12(13-25)C, and SM12 (7-18)C were also inhibitory, suggesting the presence of several protective epitopes. The synthetic peptide SM1(1-26)C, copying the NH,-terminal region of type 1 ited the glomerular cross-reaction; none of the overlapping subpeptides showed any inhibitory effect (Table 4 ). In addition, preincubation with a mixture of synthetic peptides SM12(1-12)C and SM12(13-25)C failed to inhibit immunofluorescence ( Table 4 ), suggesting that the cross-reactive antibodies are directed against a conformational epitope of SM12(1-25)C.
Identification of cross-reactive antigen. The mesangial staining pattern of cross-reactive antiserum 86142 with renal glomeruli (Fig. 2) was similar to that previously described for autoimmune antibodies evoked against SM1(1-26)C (17), suggesting that the same protein in the glomeruli may account for the cross-reactivity. We had recently shown that antibodies directed against the amino acid sequence IleArg-Leu-Arg at residues 23 through 26 of the NH2 terminus of type 1 (Table 4) . Similarly, SM12(1-25)C had no effect on the glomerular cross-reactivity of antiserum 8652 (13) raised against an NH2-terminal synthetic peptide of type 1 M protein (data not shown). Furthermore, the synthetic peptides of human vimentin SV(63-73)C and SV(178-188)C, which totally inhibited the glomerular cross-reactivity of the anti-SM1-antiserum (19) , did not inhibit renal glomerular fluorescence of antiserum 86142 ( 
